Relugolix represents oral alternative to injectable androgen deprivation therapies
In patients with localized prostate cancer undergoing external beam radiotherapy, use of the orally administered androgen deprivation therapy relugolix results in rapid and sustained suppression of testosterone to castrate levels, with a tolerable safety profile, according to the results of a phase II trial.
